

Clovis Oncology, Inc.
Form SC 13G/A
May 27, 2014

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b),

(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b)

(Amendment No. 3)*

Clovis Oncology, Inc.

(Name of Issuer)

Common Stock, par value \$0.001 per share

(Title of Class of Securities)

189464100

(CUSIP Number)

December 31, 2013

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☐ Rule 13d-1(c)
- ☒ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Edgar Filing: Clovis Oncology, Inc. - Form SC 13G/A

CUSIP No. 189464100

13 G

1	Names of Reporting Persons. Versant Side Fund IV, L.P.	
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> o (b) <input checked="" type="radio"/> x (1)	
3	SEC Use Only	
4	Citizenship or Place of Organization Delaware, United States of America	
Number of Shares Beneficially Owned by Each Reporting Person With	5	Sole Voting Power 10,200 shares of Common Stock (2)
	6	Shared Voting Power 0 shares
	7	Sole Dispositive Power 10,200 shares of Common Stock (2)
	8	Shared Dispositive Power 0 shares
9	Aggregate Amount Beneficially Owned by Each Reporting Person 10,200 shares of Common Stock (2)	
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/> o	
11	Percent of Class Represented by Amount in Row 9 0.03% (3)	
12	Type of Reporting Person* PN	

(1) This Schedule 13G is filed by Versant Side Fund IV, L.P., a Delaware limited partnership (VSF IV), Versant Venture Capital IV, L.P., a Delaware limited partnership (VVC IV), Versant Ventures IV, LLC, a Delaware limited liability company (VV IV), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Rebecca B. Robertson (RBR), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Robin L. Praeger (RLP) and Kirk G. Nielsen (KGN) and together with VSF IV, VVC IV, VV IV, BGA, SDC, RAJ, WJL, RBR, BJB, CMW and RLP, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) VV IV serves as the sole general partner of VSF IV and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, RBR, BJB, CMW, RLP and KGN are managing directors and/or members of VV IV and share voting and dispositive power over the shares held by VSF IV; however, they disclaim beneficial ownership of the shares held by VSF IV except to the extent of their pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2013.

(3) This percentage is calculated based upon 33,899,587 shares of Common Stock outstanding as of February 24, 2014 as set forth in the Issuer's most recent 10-Q filed with the Securities and Exchange Commission on February 28, 2014.

Edgar Filing: Clovis Oncology, Inc. - Form SC 13G/A

CUSIP No. 189464100

13 G

1	Names of Reporting Persons. Versant Venture Capital IV, L.P.
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)
3	SEC Use Only
4	Citizenship or Place of Organization Delaware, United States of America
5	Sole Voting Power 1,619,467 shares of Common Stock (2)
6	Shared Voting Power 0 shares
7	Sole Dispositive Power 1,619,467 shares of Common Stock (2)
8	Shared Dispositive Power 0 shares
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,619,467 shares of Common Stock (2)
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>
11	Percent of Class Represented by Amount in Row 9 4.8% (3)
12	Type of Reporting Person* PN

(1) This Schedule 13G is filed by Versant Side Fund IV, L.P., a Delaware limited partnership (VSF IV), Versant Venture Capital IV, L.P., a Delaware limited partnership (VVC IV), Versant Ventures IV, LLC, a Delaware limited liability company (VV IV), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Rebecca B. Robertson (RBR), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Robin L. Praeger (RLP) and Kirk G. Nielsen (KGN) and together with VSF IV, VVC IV, VV IV, BGA, SDC, RAJ, WJL, RBR, BJB, CMW and RLP, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) VV IV serves as the sole general partner of VVC IV and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, RBR, BJB, CMW, RLP and KGN are managing directors and/or members of VV IV and share voting and dispositive power over the shares held by VVC IV; however, they disclaim beneficial ownership of the shares held by VVC IV except to the extent of their pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2013.

(3) This percentage is calculated based upon 33,899,587 shares of Common Stock outstanding as of February 24, 2014 as set forth in the Issuer's most recent 10-Q filed with the Securities and Exchange Commission on February 28, 2014.

Edgar Filing: Clovis Oncology, Inc. - Form SC 13G/A

CUSIP No. 189464100

13 G

1	Names of Reporting Persons Versant Ventures IV, LLC
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)
3	SEC Use Only
4	Citizenship or Place of Organization Delaware, United States of America
5	Sole Voting Power 0 shares
6	Shared Voting Power 1,629,667 shares of Common Stock (2)
7	Sole Dispositive Power 0 shares
8	Shared Dispositive Power 1,629,667 shares of Common Stock (2)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,629,667 shares of Common Stock (2)
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>
11	Percent of Class Represented by Amount in Row 9 4.8% (3)
12	Type of Reporting Person* OO

(1) This Schedule 13G is filed by Versant Side Fund IV, L.P., a Delaware limited partnership (VSF IV), Versant Venture Capital IV, L.P., a Delaware limited partnership (VVC IV), Versant Ventures IV, LLC, a Delaware limited liability company (VV IV), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Rebecca B. Robertson (RBR), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Robin L. Praeger (RLP) and Kirk G. Nielsen (KGN) and together with VSF IV, VVC IV, VV IV, BGA, SDC, RAJ, WJL, RBR, BJB, CMW and RLP, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes: (i) 10,200 shares held by VSF IV and (ii) 1,619,467 shares held by VVC IV. BGA, SDC, RAJ, WJL, RBR, BJB, CMW, RLP and KGN are managing directors and/or members of VV IV and share voting and dispositive power over the shares held by VVC IV and VSF IV; however, they disclaim beneficial ownership of the shares held by VVC IV and VSF IV except to the extent of their pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2013.

(3) This percentage is calculated based upon 33,899,587 shares of Common Stock outstanding as of February 24, 2014 as set forth in the Issuer's most recent 10-Q filed with the Securities and Exchange Commission on February 28, 2014.

Edgar Filing: Clovis Oncology, Inc. - Form SC 13G/A

CUSIP No. 189464100

13 G

1	Names of Reporting Persons Brian G. Atwood
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)
3	SEC Use Only
4	Citizenship or Place of Organization United States of America
5	Sole Voting Power 58,727 shares (2)
6	Shared Voting Power 1,629,667 shares of Common Stock (3)
7	Sole Dispositive Power 58,727 shares (2)
8	Shared Dispositive Power 1,629,667 shares of Common Stock (3)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,688,394 shares of Common Stock (2)(3)
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>
11	Percent of Class Represented by Amount in Row 9 5.0% (4)
12	Type of Reporting Person* IN

(1) This Schedule 13G is filed by Versant Side Fund IV, L.P., a Delaware limited partnership (VSF IV), Versant Venture Capital IV, L.P., a Delaware limited partnership (VVC IV), Versant Ventures IV, LLC, a Delaware limited liability company (VV IV), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Rebecca B. Robertson (RBR), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Robin L. Praeger (RLP) and Kirk G. Nielsen (KGN) and together with VSF IV, VVC IV, VV IV, BGA, SDC, RAJ, WJL, RBR, BJB, CMW and RLP, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Consists of (i) 1,142 shares held by Attwood-Edminster Trust dtd 4/2/2000 for the benefit of BGA; and (ii) options to acquire 57,585 shares of Common Stock held directly by BGA for the benefit of VVIV.

(3) Includes: (i) 10,200 shares held by VSF IV and (ii) 1,619,467 shares held by VVC IV. BGA is a managing director and/or member of VV IV and shares voting and dispositive power over the shares held by VVC IV and VSF IV; however, he disclaims beneficial ownership of the shares held by VVC IV and VSF IV except to the extent of his pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2013.

(4) This percentage is calculated based upon 33,899,587 shares of Common Stock outstanding as of February 24, 2014 as set forth in the Issuer's most recent 10-Q filed with the Securities and Exchange Commission on February 28, 2014.

Edgar Filing: Clovis Oncology, Inc. - Form SC 13G/A

CUSIP No. 189464100

13 G

1	Names of Reporting Persons Samuel D. Colella
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)
3	SEC Use Only
4	Citizenship or Place of Organization United States of America
5	Sole Voting Power 570 shares (2)
6	Shared Voting Power 1,629,667 shares of Common Stock (3)
7	Sole Dispositive Power 570 shares (2)
8	Shared Dispositive Power 1,629,667 shares of Common Stock (3)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,630,237 shares of Common Stock (2)(3)
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>
11	Percent of Class Represented by Amount in Row 9 4.8% (4)
12	Type of Reporting Person* IN

(1) This Schedule 13G is filed by Versant Side Fund IV, L.P., a Delaware limited partnership (VSF IV), Versant Venture Capital IV, L.P., a Delaware limited partnership (VVC IV), Versant Ventures IV, LLC, a Delaware limited liability company (VV IV), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Rebecca B. Robertson (RBR), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Robin L. Praeger (RLP) and Kirk G. Nielsen (KGN) and together with VSF IV, VVC IV, VV IV, BGA, SDC, RAJ, WJL, RBR, BJB, CMW and RLP, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Consists of (i) 270 shares held by Colella Family Partners for the benefit of SDC; (ii) 192 shares held by Colella Family Partners III, L.P. for the benefit of SDC; and (iii) 108 shares held by Colella Family Trust UTA dtd 9/21/92 for the benefit of SDC.

(3) Includes: (i) 10,200 shares held by VSF IV and (ii) 1,619,467 shares held by VVC IV. SDC is a managing director and/or member of VV IV and shares voting and dispositive power over the shares held by VVC IV and VSF IV; however, he disclaims beneficial ownership of the shares held by VVC IV and VSF IV except to the extent of his pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2013.

(4) This percentage is calculated based upon 33,899,587 shares of Common Stock outstanding as of February 24, 2014 as set forth in the Issuer's most recent 10-Q filed with the Securities and Exchange Commission on February 28, 2014.

Edgar Filing: Clovis Oncology, Inc. - Form SC 13G/A

CUSIP No. 189464100

13 G

1	Names of Reporting Persons Ross A. Jaffe
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)
3	SEC Use Only
4	Citizenship or Place of Organization United States of America
5	Sole Voting Power 1,142 shares (2)
6	Shared Voting Power 1,629,667 shares of Common Stock (3)
7	Sole Dispositive Power 1,142 shares (2)
8	Shared Dispositive Power 1,629,667 shares of Common Stock (3)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,630,809 shares of Common Stock (2)(3)
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>
11	Percent of Class Represented by Amount in Row 9 4.8% (4)
12	Type of Reporting Person* IN

(1) This Schedule 13G is filed by Versant Side Fund IV, L.P., a Delaware limited partnership (VSF IV), Versant Venture Capital IV, L.P., a Delaware limited partnership (VVC IV), Versant Ventures IV, LLC, a Delaware limited liability company (VV IV), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Rebecca B. Robertson (RBR) Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Robin L. Praeger (RLP) and Kirk G. Nielsen (KGN) and together with VSF IV, VVC IV, VV IV, BGA, SDC, RAJ, WJL, RBR, BJB, CMW and RLP, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Consists of 1,142 shares held by Jaffe Family Trust dtd 7/9/91 for the benefit of RAJ.

(3) Includes: (i) 10,200 shares held by VSF IV; and (ii) 1,619,467 shares held by VVC IV. RAJ is a managing director and/or member of VV IV and shares voting and dispositive power over the shares held by VVC IV and VSF IV; however, he disclaims beneficial ownership of the shares held by VVC IV and VSF IV except to the extent of his pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2013.

(4) This percentage is calculated based upon 33,899,587 shares of Common Stock outstanding as of February 24, 2014 as set forth in the Issuer's most recent 10-Q filed with the Securities and Exchange Commission on February 28, 2014.

Edgar Filing: Clovis Oncology, Inc. - Form SC 13G/A

CUSIP No. 189464100

13 G

1	Names of Reporting Persons William J. Link
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)
3	SEC Use Only
4	Citizenship or Place of Organization United States of America
5	Sole Voting Power 1,843 shares (2)
6	Shared Voting Power 1,629,667 shares of Common Stock (3)
7	Sole Dispositive Power 1,843 shares (2)
8	Shared Dispositive Power 1,629,667 shares of Common Stock (3)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,631,510 shares of Common Stock (2)(3)
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>
11	Percent of Class Represented by Amount in Row 9 4.8% (4)
12	Type of Reporting Person* IN

(1) This Schedule 13G is filed by Versant Side Fund IV, L.P., a Delaware limited partnership (VSF IV), Versant Venture Capital IV, L.P., a Delaware limited partnership (VVC IV), Versant Ventures IV, LLC, a Delaware limited liability company (VV IV), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Rebecca B. Robertson (RBR), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Robin L. Praeger (RLP) and Kirk G. Nielsen (KGN) and together with VSF IV, VVC IV, VV IV, BGA, SDC, RAJ, WJL, RBR, BJB, CMW and RLP, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Consists of 1,843 shares held by Link Investments VVIV, L.P. for the benefit of WJL.

(3) Includes: (i) 10,200 shares held by VSF IV; and (ii) 1,619,467 shares held by VVC IV. WJL is a managing director and/or member of VV IV and VSF IV and shares voting and dispositive power over the shares held by VVC IV and VSF IV; however, he disclaims beneficial ownership of the shares held by VVC IV and VSF IV except to the extent of his pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2013.

(4) This percentage is calculated based upon 33,899,587 shares of Common Stock outstanding as of February 24, 2014 as set forth in the Issuer's most recent 10-Q filed with the Securities and Exchange Commission on February 28, 2014.

Edgar Filing: Clovis Oncology, Inc. - Form SC 13G/A

CUSIP No. 189464100

13 G

1	Names of Reporting Persons Rebecca B. Robertson
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)
3	SEC Use Only
4	Citizenship or Place of Organization United States of America
5	Sole Voting Power 0
6	Shared Voting Power 1,629,667 shares of Common Stock (2)
7	Sole Dispositive Power 0
8	Shared Dispositive Power 1,629,667 shares of Common Stock (2)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,629,667 shares of Common Stock (2)
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>
11	Percent of Class Represented by Amount in Row 9 4.8% (3)
12	Type of Reporting Person* IN

(1) This Schedule 13G is filed by Versant Side Fund IV, L.P., a Delaware limited partnership (VSF IV), Versant Venture Capital IV, L.P., a Delaware limited partnership (VVC IV), Versant Ventures IV, LLC, a Delaware limited liability company (VV IV), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Rebecca B. Robertson (RBR), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Robin L. Praeger (RLP) and Kirk G. Nielsen (KGN) and together with VSF IV, VVC IV, VV IV, BGA, SDC, RAJ, WJL, RBR, BJB, CMW and RLP, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes: (i) 10,200 shares held by VSF IV; and (ii) 1,619,467 shares held by VVC IV. RBR is a managing director and/or member of VV IV and VSF IV and shares voting and dispositive power over the shares held by VVC IV and VSF IV; however, she disclaims beneficial ownership of the shares held by VVC IV and VSF IV except to the extent of her pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2013.

(3) This percentage is calculated based upon 33,899,587 shares of Common Stock outstanding as of February 24, 2014 as set forth in the Issuer's most recent 10-Q filed with the Securities and Exchange Commission on February 28, 2014.

Edgar Filing: Clovis Oncology, Inc. - Form SC 13G/A

CUSIP No. 189464100

13 G

1	Names of Reporting Persons Bradley J. Bolzon
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)
3	SEC Use Only
4	Citizenship or Place of Organization Canada
5	Sole Voting Power 764 shares (2)
6	Shared Voting Power 1,629,667 shares of Common Stock (3)
7	Sole Dispositive Power 764 shares (2)
8	Shared Dispositive Power 1,629,667 shares of Common Stock (3)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,630,431 shares of Common Stock (2)(3)
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>
11	Percent of Class Represented by Amount in Row 9 4.8% (4)
12	Type of Reporting Person* IN

(1) This Schedule 13G is filed by Versant Side Fund IV, L.P., a Delaware limited partnership (VSF IV), Versant Venture Capital IV, L.P., a Delaware limited partnership (VVC IV), Versant Ventures IV, LLC, a Delaware limited liability company (VV IV), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Rebecca B. Robertson (RBR), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Robin L. Praeger (RLP) and Kirk G. Nielsen (KGN) and together with VSF IV, VVC IV, VV IV, BGA, SDC, RAJ, WJL, RBR, BJB, CMW and RLP, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Consists of 764 shares held by BJB.

(3) Includes: (i) 10,200 shares held by VSF IV; and (ii) 1,619,467 shares held by VVC IV. BJB is a managing director and/or member of VV IV and shares voting and dispositive power over the shares held by VVC IV and VSF IV; however, he disclaims beneficial ownership of the shares held by VVC IV and VSF IV except to the extent of his pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2013.

(4) This percentage is calculated based upon 33,899,587 shares of Common Stock outstanding as of February 24, 2014 as set forth in the Issuer's most recent 10-Q filed with the Securities and Exchange Commission on February 28, 2014.

Edgar Filing: Clovis Oncology, Inc. - Form SC 13G/A

CUSIP No. 189464100

13 G

1	Names of Reporting Persons Charles M. Warden
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)
3	SEC Use Only
4	Citizenship or Place of Organization United States of America
5	Sole Voting Power 0
6	Shared Voting Power 1,629,667 shares of Common Stock (2)
7	Sole Dispositive Power 0
8	Shared Dispositive Power 1,629,667 shares of Common Stock (2)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,629,667 shares of Common Stock (2)
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>
11	Percent of Class Represented by Amount in Row 9 4.8% (3)
12	Type of Reporting Person* IN

(1) This Schedule 13G is filed by Versant Side Fund IV, L.P., a Delaware limited partnership (VSF IV), Versant Venture Capital IV, L.P., a Delaware limited partnership (VVC IV), Versant Ventures IV, LLC, a Delaware limited liability company (VV IV), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Rebecca B. Robertson (RBR), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Robin L. Praeger (RLP) and Kirk G. Nielsen (KGN) and together with VSF IV, VVC IV, VV IV, BGA, SDC, RAJ, WJL, RBR, BJB, CMW and RLP, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Includes: (i) 10,200 shares held by VSF IV; and (ii) 1,619,467 shares held by VVC IV. CMW is a managing director and/or member of VV IV and shares voting and dispositive power over the shares held by VVC IV and VSF IV; however, he disclaims beneficial ownership of the shares held by VVC IV and VSF IV except to the extent of his pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2013.

(3) This percentage is calculated based upon 33,899,587 shares of Common Stock outstanding as of February 24, 2014 as set forth in the Issuer's most recent 10-Q filed with the Securities and Exchange Commission on February 28, 2014.

Edgar Filing: Clovis Oncology, Inc. - Form SC 13G/A

CUSIP No. 189464100

13 G

1	Names of Reporting Persons Robin L. Praeger
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)
3	SEC Use Only
4	Citizenship or Place of Organization United States of America
5	Sole Voting Power 354 shares (2)
6	Shared Voting Power 1,629,667 shares of Common Stock (3)
7	Sole Dispositive Power 354 shares (2)
8	Shared Dispositive Power 1,629,667 shares of Common Stock (3)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,630,021 shares of Common Stock (2)(3)
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>
11	Percent of Class Represented by Amount in Row 9 4.8% (4)
12	Type of Reporting Person* IN

(1) This Schedule 13G is filed by Versant Side Fund IV, L.P., a Delaware limited partnership (VSF IV), Versant Venture Capital IV, L.P., a Delaware limited partnership (VVC IV), Versant Ventures IV, LLC, a Delaware limited liability company (VV IV), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Rebecca B. Robertson (RBR), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Robin L. Praeger (RLP) and Kirk G. Nielsen (KGN) and together with VSF IV, VVC IV, VV IV, BGA, SDC, RAJ, WJL, RBR, BJB, CMW and RLP, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Consists of 354 shares held by Robin and Lisa Praeger for the benefit of RLP.

(3) Includes: (i) 10,200 shares held by VSF IV; and (ii) 1,619,467 shares held by VVC IV. RLP is a managing director and/or member of VV IV and shares voting and dispositive power over the shares held by VVC IV and VSF IV; however, he disclaims beneficial ownership of the shares held by VVC IV and VSF IV except to the extent of his pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2013.

(4) This percentage is calculated based upon 33,899,587 shares of Common Stock outstanding as of February 24, 2014 as set forth in the Issuer's most recent 10-Q filed with the Securities and Exchange Commission on February 28, 2014.

Edgar Filing: Clovis Oncology, Inc. - Form SC 13G/A

CUSIP No. 189464100

13 G

1	Names of Reporting Persons Kirk G. Nielsen
2	Check the Appropriate Box if a Member of a Group* (a) <input type="radio"/> (b) <input checked="" type="radio"/> (1)
3	SEC Use Only
4	Citizenship or Place of Organization United States of America
5	Sole Voting Power 102 shares (2)
6	Shared Voting Power 1,629,667 shares of Common Stock (3)
7	Sole Dispositive Power 102 shares (2)
8	Shared Dispositive Power 1,629,667 shares of Common Stock (3)
9	Aggregate Amount Beneficially Owned by Each Reporting Person 1,629,769 shares of Common Stock (2)(3)
10	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares* <input type="radio"/>
11	Percent of Class Represented by Amount in Row 9 4.8% (4)
12	Type of Reporting Person* IN

(1) This Schedule 13G is filed by Versant Side Fund IV, L.P., a Delaware limited partnership (VSF IV), Versant Venture Capital IV, L.P., a Delaware limited partnership (VVC IV), Versant Ventures IV, LLC, a Delaware limited liability company (VV IV), Brian G. Atwood (BGA), Samuel D. Colella (SDC), Ross A. Jaffe (RAJ), William J. Link (WJL), Rebecca B. Robertson (RBR), Bradley J. Bolzon (BJB), Charles M. Warden (CMW), Robin L. Praeger (RLP) and Kirk G. Nielsen (KGN) and together with VSF IV, VVC IV, VV IV, BGA, SDC, RAJ, WJL, RBR, BJB, CMW and RLP, collectively, the Reporting Persons). The Reporting Persons expressly disclaim status as a group for purposes of this Schedule 13G.

(2) Consists of 102 shares held by KGN.

(3) Includes: (i) 10,200 shares held by VSF IV; and (ii) 1,619,467 shares held by VVC IV. KGN is a managing director and/or member of VV IV and shares voting and dispositive power over the shares held by VVC IV and VSF IV; however, he disclaims beneficial ownership of the shares held by VVC IV and VSF IV except to the extent of his pecuniary interests therein. The information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2013.

(4) This percentage is calculated based upon 33,899,587 shares of Common Stock outstanding as of February 24, 2014 as set forth in the Issuer's most recent 10-Q filed with the Securities and Exchange Commission on February 28, 2014.

Edgar Filing: Clovis Oncology, Inc. - Form SC 13G/A

Introductory Note: This Statement on Schedule 13G is filed on behalf of the Reporting Persons, in respect of shares of Common Stock, par value \$0.001 per share (Common Stock), of Clovis Oncology, Inc. (the Issuer).

Item 1

- (a) Name of Issuer:
Clovis Oncology, Inc.
Address of Issuer's Principal Executive Offices:
2525 28th Street, Suite 100

Boulder, Colorado 80301

Item 2

- (a) Name of Person(s) Filing:
Versant Side Fund IV, L.P. (VSF IV)

Versant Venture Capital IV, L.P. (VVC IV)

Versant Ventures IV, LLC (VV IV)

Brian G. Atwood (BGA)

Samuel D. Colella (SDC)

Ross A. Jaffe (RAJ)

William J. Link (WJL)

Rebecca B. Robertson (RBR)

Bradley J. Bolzon (BJB)

Charles M. Warden (CMW)

Robin L. Praeger (RLP)

- (b) Kirk G. Nielsen (KGN)
Address of Principal Business Office:
c/o Versant Ventures

3000 Sand Hill Road

Building 4, Suite 210

Menlo Park, California 94025

- (b) Citizenship:
Entities:
- | | | |
|--------|---|------------------------------------|
| VSF IV | - | Delaware, United States of America |
| VVC IV | - | Delaware, United States of America |
| VV IV | - | Delaware, United States of America |
- Individuals:
- | | | |
|-----|---|--------------------------|
| BGA | - | United States of America |
| SDC | - | United States of America |
| RAJ | - | United States of America |

Edgar Filing: Clovis Oncology, Inc. - Form SC 13G/A

		WJL	-	United States of America
		RBR	-	United States of America
		BJB	-	Canada
		CMW	-	United States of America
		RLP	-	United States of America
		KGN	-	United States of America
(d)	Title of Class of Securities:			
	Common Stock			
(e)	CUSIP Number:			
	189464100			

Item 3 Not applicable.

Item 4**Ownership.**

The following information with respect to the ownership of the Common Stock by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2013:

Reporting Persons	Shares Held Directly	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Beneficial Ownership	Percentage of Class (2)
VSF IV	10,200	10,200	0	10,200	0	10,200	0.03%
VVC IV	1,619,467	1,619,467	0	1,619,467	0	1,619,467	4.8%
VV IV	0	0	1,629,667	0	1,629,667	1,629,667	4.8%
BGA	58,727	58,727	1,629,667	58,727	1,629,667	1,688,394	5.0%
SDC	570	570	1,629,667	570	1,629,667	1,630,237	4.8%
RAJ	1,142	1,142	1,629,667	1,142	1,629,667	1,630,809	4.8%
WJL	1,843	1,843	1,629,667	1,843	1,629,667	1,631,510	4.8%
RBR	0	0	1,629,667	0	1,629,667	1,629,667	4.8%
BJB	764	764	1,629,667	764	1,629,667	1,630,431	4.8%
CMW	0	0	1,629,667	0	1,629,667	1,629,667	4.8%
RLP	354	354	1,629,667	354	1,629,667	1,630,021	4.8%
KGN	102	102	1,629,667	102	1,629,667	1,629,769	4.8%

(1) VV IV serves as the sole general partner of VSF IV and VVC IV and owns no securities of the Issuer directly. BGA, SDC, RAJ, WJL, RBR, BJB, CMW, RLP and KGN are managing directors and/or members of VV IV and share voting and dispositive power over the shares held by VSF IV and VVC IV; however, they disclaim beneficial ownership of the shares held by VSF IV and VVC IV except to the extent of their pecuniary interests therein.

(2) This percentage is calculated based upon 33,899,587 shares of Common Stock outstanding as of February 24, 2014 as set forth in the Issuer's most recent 10-Q filed with the Securities and Exchange Commission on February 28, 2014.

Item 5**Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ☐

Item 6**Ownership of More than Five Percent on Behalf of Another Person.**

See Items 2(a) and 4.

Item 7**Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.**

Not applicable.

Item 8**Identification and Classification of Members of the Group.**

Not applicable.

Item 9**Notice of Dissolution of Group.**

Not applicable.

Item 10 **Certification.**
Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: May 27, 2014

Versant Side Fund IV, L.P.

By: Versant Ventures IV, LLC
Its: General Partner

By: /s/ Robin L. Praeger
 Authorized Representative

Versant Venture Capital IV, L.P.

By: Versant Ventures IV, LLC
Its: General Partner

By: /s/ Robin L. Praeger
 Authorized Representative

Versant Ventures IV, LLC

By: /s/ Robin L. Praeger
 Managing Member

/s/ Robin L. Praeger as attorney in fact
Brian G. Atwood

/s/ Robin L. Praeger as attorney in fact
Samuel D. Colella

/s/ Robin L. Praeger as attorney in fact
Ross A. Jaffe

/s/ Robin L. Praeger as attorney in fact
William J. Link

/s/ Robin L. Praeger as attorney in fact
Rebecca B. Robertson

/s/ Robin L. Praeger as attorney in fact
Bradley J. Bolzon

/s/ Robin L. Praeger as attorney in fact
Charles M. Warden

/s/ Robin L. Praeger
Robin L. Praeger

/s/ Robin L. Praeger as attorney in fact
Kirk G. Nielsen

Exhibit(s):

A - Joint Filing Statement

EXHIBIT A

JOINT FILING STATEMENT

We, the undersigned, hereby express our agreement that the attached Schedule 13G (or any amendments thereto) relating to the Common Stock of Clovis Oncology, Inc. is filed on behalf of each of us.

Dated: May 27, 2014

Versant Side Fund IV, L.P.

By: Versant Ventures IV, LLC
Its: General Partner

By: /s/ Robin L. Praeger
Authorized Representative

Versant Venture Capital IV, L.P.

By: Versant Ventures IV, LLC
Its: General Partner

By: /s/ Robin L. Praeger
Authorized Representative

Versant Ventures IV, LLC

By: /s/ Robin L. Praeger
Managing Member

/s/ Robin L. Praeger as attorney in fact
Brian G. Atwood

/s/ Robin L. Praeger as attorney in fact
Samuel D. Colella

/s/ Robin L. Praeger as attorney in fact
Ross A. Jaffe

/s/ Robin L. Praeger as attorney in fact
William J. Link

/s/ Robin L. Praeger as attorney in fact
Rebecca B. Robertson

/s/ Robin L. Praeger as attorney in fact
Bradley J. Bolzon

/s/ Robin L. Praeger as attorney in fact
Charles M. Warden

/s/ Robin L. Praeger
Robin L. Praeger

/s/ Robin L. Praeger as attorney in fact
Kirk G. Nielsen